The Use of Amantadine in a Patient with Pneumonia and Parkinson’s Disease: A Case Report

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide, with an annual incidence of 8–18 per 100,000 individuals. Its prevalence rises significantly in populations aged 60 and older, with cases projected to double by 2030. While amantadine is well-recognized for managing dyskinesia and as initial monotherapy in PD, its utility in addressing PD decompensation remains insufficiently studied. This report details the case of a 72-year-old Asian woman with PD who developed bilateral lower lobe pneumonia with a prolonged fever. Her condition was marked by worsening motor symptoms, including increased rigidity and tremors. An intravenous infusion of amantadine sulfate was administered, resulting in notable improvements in muscle tone, rigidity, and tremor control. This case highlights the potential role of amantadine in stabilizing motor function during acute systemic stress, such as severe infections. The findings suggest that amantadine sulfate may serve as an effective therapeutic option for PD decompensation in complex clinical scenarios involving comorbid conditions. This case underscores the need for further investigation to define the therapeutic range and establish targeted treatment protocols for PD patients requiring critical care interventions.